ImStem Biotechnology, a biopharmaceutical company located in UConn’s Technology Incubation Program (TIP), recently announced the U.S. FDA has removed the clinical hold on ImStem’s Investigational New Drug (IND) to evaluate their cell product candidate for the treatment of multiple sclerosis.

Multiple sclerosis is a potentially disabling disease of the brain and spinal cord. There is no cure, but the right treatments can help manage the disease. Dr. Jaime Imitola explains how UConn Health’s Multiple Sclerosis Center offers comprehensive and compassionate care that can help guide you through the process from diagnosis to long-term therapy.  

More than 160 students from 37 high schools throughout Connecticut came to UConn Health for the Connecticut Regional Junior Science and Humanities Symposium, organized by the Connecticut Area Health Education Center.

Dry eye is a common and often chronic condition that affects people of all ages—but particularly older adults. As UConn Health ophthalmologist Ana Morales explains, if the condition advances untreated, it may damage the eye and impair vision.

UConn Health and its faculty have been applauded on the national stage for their accomplishments. The most recent accolades include: Early Career Scientist Receive Prestigious Grant from AFAR and The Glenn Foundation for Medical Research The American Federation for Aging and Research (AFAR) and The Glenn Foundation for Medical Research have announced Ming Xu, PhD, […]